Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study.

Date publication

septembre 2019

Journal

Clinical colorectal cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi

Tous les auteurs :
Auvray M, Tougeron D, Auclin E, Moulin V, Artru P, Hautefeuille V, Hammel P, Lecomte T, Locher C, Sickersen G, Coriat R, Lecaille C, Vernerey D, Taieb J, Pernot S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31648924

Résumé

Although no data have been reported beyond second-line therapy, aflibercept is approved in this setting in many countries. We conducted a multicenter study to analyze the efficacy and safety of a aflibercept-chemotherapy regimen beyond second-line therapy in patients with metastatic colorectal cancer.

Mots clés

Acquired resistance, Advanced disease, Antiangiogenic, Metastatic colorectal cancer, Outcomes

Référence

Clin Colorectal Cancer. 2019 Sep 4;: